ELISA News and Research

RSS

COVID mRNA vaccines display weakened immune response with age and diminish over time, according to new study

Researchers from Simon Fraser University in Canada decided to investigate the magnitude of immunity in mRNA vaccines for COVID-19.

15 Sep 2021

Quantification of salivary IgG and IgA against SARS-CoV-2

Salivary antibody levels are many fold lower than found in blood serum, Immunoglobulin G (IgG) in the saliva is mainly sourced from leakage from the gingival surface and Immunoglobulin A (IgA) from mucosal membranes.

15 Sep 2021

An oral COVID-19 vaccine induces mucosal and protective immunity

Researchers have collaborated to resolve the aforementioned problems associated with injection vaccines to create a thermostable vaccine that can be taken orally.

13 Sep 2021

No evidence of pre-existing antibody and B cell immunity against SARS-CoV-2 in unexposed adults

A group of researchers analyzed the B cell response to SARS-CoV-2 in unexposed individuals.

10 Sep 2021

Multiplexed electrochemical sensor platform enables simultaneous detection of SARS-CoV-2 RNA and host antibodies

Scientists from the UK and USA have developed an antifouling nanocomposite-coated multiplexed electrochemical sensor platform that can simultaneously detect severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA and virus-specific antibodies. The platform has shown 100% accuracy in detecting viral RNA and IgG-specific anti-SARS-CoV-2 antibodies. The study is currently available on the medRxiv* preprint server.

6 Sep 2021

Regional differences in prevalence of SARS-CoV-2 antibodies in children

A population-based study assesses seroprevalence in a representative sample of children from regions with high and low community transmission.

2 Sep 2021

An assessment of post-vaccination immune response to SARS-CoV-2 Delta in elderly and health care workers

A new cohort study comparing immune responses among vaccinated elderly persons and healthcare workers has been conducted.

2 Sep 2021

Sustained and effective response to Janssen COVID-19 vaccine Is enhanced by delayed booster

A new study adds to the data on the optimum interval between the first and second doses of the adenovirus vectored COVID-19 vaccine.

30 Aug 2021

The impact of mild SARS-CoV-2 infection on maternal-fetal immunity

Recently, a new study published on the pre-print server bioRxiv* examined the effect that maternal asymptomatic COVID-19 had on decidual and peripheral immune cells during the later stage of pregnancy.

30 Aug 2021

Combination therapy disables PI3K/Akt/mTOR pathway and induces apoptosis in carcinoid syndrome

Oncotarget published "Next-generation multimodality of nutrigenomic cancer therapy: sulforaphane in combination with acetazolamide actively target bronchial carcinoid cancer in disabling the PI3K/Akt/mTOR survival pathway and inducing apoptosis" which reported that microscopic imaging, immunocytochemistry, wound healing assay, caspase-cleaved cytokeratin 18 CytoDeath ELISA assay, immunofluorescence labeling assays for apoptosis, hypoxia, Western Blotting, Tunnel assay, measurement of 5-HT secretion by carbon fiber amperometry assay, quantitative methylation-specific PCR, morphologic changes, cell viability, apoptosis activity and the expression levels of phospho-Akt1, Akt1, HIF-1α, PI3K, p21, CAIX, 5-HT, phospho-mTOR, and mTOR in xenografts derived from typical H727 and atypical H720 BC cell lines.

28 Aug 2021

Compounds from medicinal mushrooms may be our future weapon against SARS-CoV-2

Certain steroid-like compounds from Taiwan's endemic medicinal mushrooms (known as antcins) may inhibit a host cell receptor for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and, thus, prevent viral infection and subsequent development of the coronavirus disease (COVID-19), reports a new study published in the MDPI's journal Plants.

24 Aug 2021

Study shows difference in antibody levels in response to SARS-CoV-2 infection and type of vaccination

In a recent study, researchers aimed to monitor the levels of the anti-SARS-CoV-2 spike IgG levels in populations that were subjected to routine tests.

24 Aug 2021

COVID booster shots might be needed in subgroup of HIV-positive individuals

The coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has evolved into a global pandemic destroying lives and economies. COVID-19 is not curable, so vaccines are the only safeguard during this pandemic.

23 Aug 2021

Nanotechnology provides novel solutions against zoonotic viruses

Therefore, scientists functionalize nanoparticles to act against these pathogenic viruses in a clinical strategy. In a recent review published in the journal Microbial Pathogenesis, researchers look at the novel solutions against zoonotic viruses provided by nanotechnology.

23 Aug 2021

A combination of oral bacteria and intranasal vaccine provide protection from influenza A virus and COVID-19

A new study published in the journal mBio focuses on the role of nasal bacteria in eliciting virus-specific adaptive immunity.

20 Aug 2021

Small study suggests a mix-and-match COVID-19 booster produces robust antibody levels

In a small study published in the medRxiv* preprint server, people given a booster Johnson & Johnson COVID-19 shot showed elevated and robust antibody levels.

19 Aug 2021

Scientists identify a potent neutralizing nanobody against SARS-CoV-1

In a recently published article in the journal Virologica Sinica, scientists have described the development and validation of a potent nanobody that targets the receptor-binding domain (RBD) of severe acute respiratory syndrome coronavirus (SARS-CoV). The nanobody efficiently and specifically blocks the interaction between RBD and angiotensin-converting enzyme 2 (ACE2) and neutralizes the virus.

19 Aug 2021

Sino Biological Announces Successful Closing of 4.98 Billion RMB Public Offering and Listing on the Shenzhen ChiNext Stock Exchange

Sino Biological, Inc. (“Sino Biological” or the “Company”), a biotechnology company which provides biological research reagents and related technical contract research services, announced a successful listing on the Shenzhen Stock Exchange subsidiary ChiNext under the stock abbreviation Sino Biological and stock code 301047.

From Sino Biological Inc. 17 Aug 2021

How delta and kappa variants of SARS-CoV-2 evade the immune system

A new study, available on the bioRxiv* preprint server, describes the neutralizing ability of the monoclonal antibodies against the variants and the difference of the ACE2 binding affinity found in the variants.

17 Aug 2021

Primate study shows benefit of mRNA vaccine booster shot against SARS-CoV-2 variants

In a recent bioRxiv* preprint research paper, a large group of US scientists demonstrate how a booster dose of the mRNA-1273 vaccine can substantially improve both the potency and range of neutralizing antibody responses and mediate protection against upper and lower airway infection by a range of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern – even those relatively resistant to in vitro neutralization.

16 Aug 2021